<DOC>
	<DOC>NCT02193139</DOC>
	<brief_summary>This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.</brief_summary>
	<brief_title>Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Healthy volunteers with primary axillary hyperhidrosis Poor quality of life rating on the Hyperhidrosis Disease Severity Scale (score of 3 or 4) Has a baseline gravimetric measurement of spontaneous resting sweat production of â‰¥100 mg/10 min at room at room temperature in at least one axilla Meets at least two of the following criteria (selfreported): sweating is bilateral and symmetrical excessive sweating impairs daily activities subject experiences at least one sweating episode per week excessive sweating onset was earlier than age 25 years has a positive family history for excessive sweating cessation of sweating during sleep</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>